Physician profile
Scott D Curry
NPI 1144206640
$752.68
in general payments reported to CMS, 2019-2025
10 companies · $43.41 in 2025
The $43.41 reported for 2025 was less than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $177 · 2020: $117 · 2021: $82.28 · 2022: $142 · 2023: $84.71 · 2024: $106 · 2025: $43.41.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $234.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $233.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerin Medical INC. | $225.65 | 2020-2022 | |
| Cumberland Pharmaceuticals, INC. | $133.62 | 2021-2023 | Caldolor |
| Regeneron Healthcare Solutions, INC. | $92.02 | 2019-2025 | Dupixent |
| Stryker Corporation | $87.75 | 2019 | |
| Acclarent, INC | $77.03 | 2019-2024 | Trudi Nav Cable, Acclarent Aera |
| Genzyme Corporation | $39.58 | 2023 | |
| Optinose US, INC. | $34.25 | 2019 | |
| Integra Lifesciences Corporation | $26.27 | 2024 | Inspira Air, Acclarent Aera, Trudi Probe |
| Glaxosmithkline, LLC. | $20.28 | 2024 | Nucala |
| Smith+Nephew, INC. | $16.23 | 2024 | Halo, Rf20000, Ent Sinus |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Curry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.